AKT1 and cancer: Existing studies have demonstrated the potential of targeting some relevant signaling pathways in cancer therapy, like hypoxia-inducible factor-1 (Ma et al., 2021), Notch pathway (Hu et al., 2012), growth factor signaling (Lowery & Yu, 2012), PI3K/AKT pathway (Yu, Wei & Liu, 2022), MAPK pathway (Kciuk et al., 2022), and Wnt/β-catenin pathway (Wang, Li & Ji, 2021), to name a few.